Pyxis Oncology (PYXS) News Today

Pyxis Oncology, Inc. (NASDAQ:PYXS) saw its shares move higher today amid a series of analyst actions and corporate event announcements that suggest growing institutional interest and improved outlook for the clinical‐stage cancer therapeutics developer.

• Positive Sentiment: HC Wainwright reiterated its “Buy” rating on PYXS and maintained a $5.00 price target, reflecting continued confidence in the company’s pipeline and upside potential. HC Wainwright Reiterates Buy Rating for Pyxis Oncology (NASDAQ:PYXS)
• Positive Sentiment: HC Wainwright raised its EPS forecasts for PYXS across multiple upcoming reporting periods—from Q3 2025 through FY 2029 (e.g., Q3 2025: –$0.37 vs. –$0.40 prior; FY 2025: –$1.42 vs. –$1.55 prior; FY 2026: –$1.35 vs. –$1.46 prior; FY 2029: $0.20 vs. $0.18 prior)—while keeping its Buy rating and $5 target. HC Wainwright Raises PYXS EPS Estimates
• Positive Sentiment: Pyxis announced that CEO Lara S. Sullivan, M.D. will present at multiple investor and industry conferences in September, increasing the company’s visibility among analysts and potential partners. Pyxis Oncology to Participate in September Investor and Industry Conferences
• Neutral Sentiment: Zacks Research upgraded PYXS from a “Strong Sell” to a “Hold” rating, reflecting a reduced downside view but stopping short of a positive endorsement. Pyxis Oncology (NASDAQ:PYXS) Raised to Hold at Zacks Research